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Precision medicine applied to psychiatry provides new insight into the promising field
of precision psychiatry. Psychotic disorders are heterogeneous, complex, chronic, and
severe mental disorders. Not only does the prognosis and the course of the disease vary
among patients suffering from psychotic disorders, but the treatment response varies as
well. Although antipsychotic drugs are the cornerstone of the treatment of schizophrenia,
many patients only partially respond to these drugs. Furthermore, patients often
experience adverse events which can lead to poor treatment adherence. Interindividual
variability in drug response could be related to age, gender, ethnicity, lifestyle factors,
pharmacological interactions, obesity, and genetics, all of which influence the process of
drug metabolism. Commonly prescribed antipsychotics are metabolized by cytochrome
P450 (CYP450) enzymes, and CYP450 genes are highly polymorphic. Pharmacogenetic
testing is increasingly being used to predict a patient’s drug response and could help
to find the most appropriate therapy for an individual patient. In this report, we describe
a psychotic patient who did not receive adequate clinical follow-up and subsequently
presented adverse events, which could be explained by his pharmacogenetic profile and
the drug interactions resulting from the polypharmacy prescribed.
Keywords: antipsychotic agents, pharmacogenetics, cytochrome P450 enzyme system, psychotic disorders,
precision medicine

INTRODUCTION
An increasing number of children, adolescents, and adults (1) are being diagnosed with mental
illness, including depressive disorder, bipolar disorder, and schizophrenia spectrum disorder (2–7).
According to the World Health Organization (8), people with mental disorders experience higher
rates of disability and mortality compared to the general population, making these conditions a
priority of health systems.
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Psychotic disorders are a group of heterogeneous, complex,
chronic, and severe mental diseases that manifest through
positive (hallucinations, delusions, etc.) and negative (impaired
motivation, social withdrawal, etc.) symptoms, affecting
approximately 1% of the global population (9, 10). Not only are
the prognosis and disease course of psychotic disorders variable
among patients, but so is treatment response. Antipsychotic
drugs comprise the fundamental treatment of schizophrenia and
other psychotic disorders (11, 12), but many patients do not
only partially respond to drug therapy (13, 14). Furthermore,
patients often experience side effects when taking antipsychotics
including sedation, cognitive impairment, weight gain and
obesity, metabolic syndrome, cardiovascular and neuromotor
side effects, among others, which can lead to poor adherence or
discontinuation of treatment (15–19).
Interindividual variability in the hepatic metabolism of these
drugs may be impacted by several factors including age, gender,
ethnicity, lifestyle factors (e.g., tobacco and alcohol consumption,
diet), pharmacological interactions (patients taking multiple
drugs), obesity, and variation in the genes contributing to
the metabolism of the drugs taken (20–22). Many commonly
prescribed antipsychotics are metabolized by cytochrome P450
enzymes, mainly CYP2C19 and CYP2D6 (23–26).
CYP genes are highly polymorphic, and patients with extreme
phenotypes, i.e., those with no or low activity or increased
activity, have been shown to have an increased risk of adverse
events or treatment failure due to drug levels that are either
too high or too low (27, 28). Thus, pharmacogenetic testing is
increasingly utilized to predict a patient’s metabolic capacity
and utilize this knowledge to inform drug therapy (29–33).
Variable enzyme activity can to a large part be explained by
the presence of variations on the nucleotide level [i.e., singlenucleotide polymorphisms (SNPs)] but also be caused by
gene copy number variation (CNVs), i.e., gene duplications or
deletions, and rearrangements (34, 35). Genotype is typically
translated into phenotype [i.e., poor metabolizers (PM),
intermediate metabolizers (IM), normal metabolizers (NMs),
rapid metabolizers (RMs), and ultrarapid metabolizers (UMs)]
and therapeutic recommendations based thereof. For CYP2D6
genotype to phenotype translation, recommendations have been
published by the Clinical Pharmacogenetics Implementation
Consortium (36). Additional details and translation tables for
other CYPs can be found on the PharmGKB website at https://
www.pharmgkb.org/page/pgxGeneRef.
CYP2D6 is one of the most important and extensively
studied CYP450 enzymes (34, 37). It has been shown to
contribute to the metabolism of over 20% of commonly
prescribed medications (38) including atypical antipsychotics
such as aripiprazole, asenapine, clozapine, olanzapine,
quetiapine, and risperidone. To date, the Pharmacogene
Variation Consortium (39, 40) has described over 140
variant alleles (star alleles) (41). Approximately 5–10%
of the European population are poor metabolizers due to
having two nonfunctional alleles (42). Additional information
regarding allele and genotype frequencies can be found on the
PharmGKB website.
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In this report, we describe a psychotic patient who did
not receive adequate clinical follow-up and presented
with side effects, which could have been prevented
considering pharmacogenetic test results, complex history,
and polypharmacy.

CASE DESCRIPTION
The following report describes the situation of a male European
patient, who gave us consent to publish his situation, who
was born in 1956, and who had been receiving mental health
care since 1993, initially under private care, with a diagnosis
of schizotypal personality disorder (DSM-V, F21). Regarding
the psychiatric family history, his father suffered from bipolar
disorder (DSM-V, F31), and his brothers suffered from major
depressive disorder (DSM-V, F33). The review of the family
history also revealed a psychotic disorder in a second-degree
relative (niece). Somatic personal history included hemorrhoids
and an anal fissure. The patient did not smoke, drink alcohol,
or have a history of substance abuse. During the routine clinical
analysis performed throughout the study, there were no ionic,
metabolic, or hematological alterations found. In 1994, during
his first admission at the University Hospital of Salamanca, he
was diagnosed with schizoaffective disorder bipolar type (DSMV, F25.0). From 1994 to 2015, follow-up treatment was carried
out with no hospital admissions and no documented adverse
events (AE). In the months following his mother’s death and
the admission of this father into a care facility, the patient
overdosed on lithium with autolytic intention, which required a
3-day stay in intensive care. After this event, the patient clinically
deteriorated, and his treatment was changed in seven phases (see
Figure 1A):
1st treatment plan (1994–18/01/2016): The first admission
was triggered by hypomanic symptoms (expansive mood,
ideo-fleeting speech, decreased sleep needs, and maniform
symptomatology), after which he was diagnosed with
schizoaffective disorder. The treatment prescribed when
he was described was as follows: lithium, amisulpride,
escitalopram, trazodone, and clobazam. No documented
AE. After a sudden change in his familiar environment, the
patient overdosed on lithium, with autolytic intention, which
required a 3-day stay in intensive care, and was hospitalized
for 43 days (6/12/2015–18/01/2016), presenting with rudeness,
inappropriate sexual behavior, childish utterances, emotional
coldness, and antagonistic behavior. Previous treatment
was continued with minor extrapyramidal effects. For
pharmacogenetic interactions (see Figure 1B).
2nd treatment plan (18/01/2016–13/06/2016): Based on the
adverse effect referred by the patient and taking into account
his poor clinical progress during the last hospitalization, the
prescriber adjusted the drug treatment upon the patient’s
release to only include lithium and amisulpride, neither
of which is metabolized by a CYP enzyme. Although this
adjustment reduced adverse effects, the patient’s clinical
condition did not improve, and he was readmitted for 49
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days (25/04/2016–13/06/2016) due to disturbed behavior with
neither depressive nor psychotic symptomatology whereupon
he was treated with amisulpride, lorazepam, lormetazepam,
quetiapine, and fluoxetine with deep venous thrombosis and
gastrointestinal bleeding (melena) as AE.
A pharmacogenetic test [AmpliChip CYP450 Test (43),
the Antigenomics platform, MassARRAY 4.2 (Agena), and
probed-based assays using the Light-Cycler platform] was
performed while the patient was hospitalized. The following
allelic variants were tested: CYP2B6 (∗ 6), CYP2C9 (∗ 2 and
∗ 3), CYP2C19 (∗ 2, ∗ 3, and ∗ 17), CYP2D6 (∗ 2, ∗ 3, ∗ 4, ∗ 5,
∗ 6, ∗ 7, ∗ 8, ∗ 9, ∗ 10, ∗ 12, ∗ 14, ∗ 17, ∗ 29, ∗ 41, and presence
of gene duplication), CYP3A4 (−392 G>A), CYP3A5 (∗ 3),
and MDR1 (3435C>T) (Table 1). Allele nomenclature was
per the Pharmacogenetic Variation (PharmVar) Consortium

(41). The CYP2D6 genotype, however, was returned as a
“no call”. Subsequent gene resequencing revealed that the
patient had a novel allele, which was submitted to PharmVar
(41) and designated CYP2D6∗ 119. The genotype of the
patient was revised to CYP2D6∗ 4/∗ 119. The CYP2D6∗ 119 allele
shares many sequence variants with the decreased function
CYP2D6∗ 41 allele but lacks 2851C>T (p.R296C). Due to the
presence of 2989G>A which has been shown to impact splicing,
the CYP2D6∗ 119 allele may have decreased function (PMID
33043448); thus we classified the patient as an IM (it is noted
though that CPIC classified this alleles as “unknown function”).
PM status for CYP3A5 and decreased expression of the MDR1
drug transporter were also discovered.
3rd treatment plan (13/06/2016–04/10/2016): Upon
discharge, a treatment readjustment was made, as the

FIGURE 1 | (A) Clinical history of the patient from 1994 to the end of the case study. *Therapeutic plan is slightly modified due to the patient’s complaints of insomnia.
#One of the antipsychotics used is discontinued due to the appearance of hyperprolactinemia. † After stabilizing a hypomanic episode, olanzapine (oral) is substituted
by aripiprazole (LAI), and therapy is readjusted to control insomnia. (B) Pharmacotherapy doses. Daily doses administered through the different stages of the patient
clinical evolution. Mg, milligram; D, day.
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and amisulpride was suspended. The patient was hospitalized
for 9 days (22/02/2017–03/03/2017) because of behavioral
disturbances and depressed mood with delusions of guilt
and harm, exhibiting mutism and a catatonic attitude.
Treatment was continued with extrapyramidal effects during
the hospitalization.
5th treatment plant (February 2017–May 2017): The patient
was discharged with aripiprazole, lithium, clonazepam,
lormetazepam, and citalopram. Minor extrapyramidal effects.
Hospitalized for 12 days (06/05/2017–18/05/2017), due
to disorganized behavior and refusal to take medication,
with
olanzapine,
citalopram,
lithium,
clonazepam,
and lormetazepam.
6th treatment plant (May 2017–December 2017): At
discharge, the patient continued with olanzapine, clonazepam,
lormetazepam, and lorazepam. The patient presented
extrapyramidal symptoms after administration of haloperidol
due to a manic episode managed as an outpatient.
7th treatment plant (from December 2017): Given the need
to control the patient’s sleep pattern and in light of the sedative
effects of olanzapine, olanzapine was replaced with aripiprazole,
eventually a long-acting injectable (LAI), to ensure adherence
and simplify the absorption variables, complementing the
therapy with lithium, clonazepam, lormetazepam, and
pregabalin. From this point, the patient did not present AE, nor
needed hospitalization.

potential increase in quetiapine plasma levels due to the
quetiapine-fluoxetine pharmacokinetic interaction was thought
to be related to the emergence of the deep venous thrombosis,
combined with the fact that the hospital stay was prolonged,
and the patient could have been bedridden longer than usual.
The new prescription consisted of lorazepam, amisulpride,
valproate, escitalopram, and trazodone. There were no
documented AE, but required two hospitalizations of 9 days
(04/07/2016–13/07/2016), due to behavioral disturbances in
response to a change of residence, and 21 days (13/09/2016–
04/10/2016), due to an exacerbation of the hypomanic
symptomatology. Previous treatment was continued with
minor extrapyramidal effects and insomnia.
4th treatment plan (October 2016–February 2017): Given
the profile of adverse effects reported by the patient (excessive
morning sedation and extrapyramidal symptoms) and the fact
that the patient was not receiving a satisfactory therapeutic
benefit, the pharmacological treatment was readjusted to
amisulpride, olanzapine, valproate, and levomepromazine.
Hyperprolactinemia was found in a routine clinical analysis,

TABLE 1 | Pharmacogenetic analysis.
Gene

Alleles tested

Genotype

Predicted phenotype

CYP2C19

*2, *3, *17

*1/*1

CYP2D6

2-*10, *12, *14,
*17, *29, *41,
XN

*4/*119

CYP2C9

*2, *3

*1/*1

Normal metabolizer

CYP2B6

*6

*1/*1

Normal metabolizer

CYP3A4

−392 G>A

A/A

Normal metabolizer

CYP3A5

*3

*3/*3

Poor metabolizer

3435C>T

C/T

Decreased expression

MDR1

Normal metabolizer
Intermediate metabolizer

DISCUSSION
We present a patient with a novel CYP2D6 allele, CYP2D6∗ 119,
which was paired with a known non-functional allele. Since
the novel allele and CYP2D6∗ 41, a known decreased function
allele, essentially only differ by an SNP that is believed to
not alter the enzymatic activity, we classified the patient as
IM. This phenotype (i.e., decreased CYP2D6 activity) may
have contributed to the extrapyramidal AE presented after
administration of levomepromazine and haloperidol, and the

Alleles listed using the PharmVar Haplotype nomenclature. *Allele.
Phenotype predictions are according to those recommend by CPIC which are
summarized by respective “diplotype to phenotype translation” tables (available at: https://
www.pharmgkb.org/page/pgxGeneRef).

TABLE 2 | Pharmacogenetic interaction of all treatment of the patient.
Cytochrome P450
1A2

2B6

2C8

2C9

2C19

2D6 (*)

2E1

3A4

3A5 († )

3A7

MDR1 (‡ )

S (+)

S (-)

S (-)

S

Amisulpride

S

Aripiprazole

S (+), Ih Id

Escitalopram
Fluoxetine

S, Ih

S, Ih

S, Ih

S (+) Ih

S (+)

S (-) Ih

S (+) Ih

S (+) Ih

S

Ih, S (+)

Ih

Levomepromazine

S (-)

S

S (+) Ih

S

Lithium
Olanzapine

S (+)

Ih

Quetiapine

Ih

S (±) Ih

Ih

S (-)

S (±) Ih

S (+)

S (-)

S (-)

S (+)

S (+)

S (-)

S (-)

Trazodone
Valproate

Ih

S (+) Ih

S (-) Ih

Ih

S

Id

*CYP2D6*4/*119, CYP2D6 predicted intermediate metabolizer (IM) phenotype. † CYP3A5*3/*3 predicted poor metabolizer (PM) phenotype. ‡ MDR1 3435C/3435T predicted
decreased expression.
Id (Inducer). Ih (Inhibitor). S (Substrate). + (Major Metabolic Pathway), ± (Minor Metabolic Pathway), - (Minor Metabolic Pathway likely not clinically relevant).
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(i.e., antipsychotic plasma levels). Moreover, this methodology
was introduced, concurring with the increasing use of LAI
presentations, which facilitate therapeutic adherence, and it
could be a possible confounder. One of the strong points of this
approach is that the decisions concerning the pharmacotherapy
of the patient were agreed to by a multidisciplinary team
(in which psychiatrists and clinical biochemists, among other
clinical specialties, participated), which permitted a more
profound knowledge about the drug metabolism and the factors
influencing drug varying factors and promoted education on
this subject for the bio-sanitary personnel (including psychiatric,
nurses, psychologist, etc.).

sedation associated with olanzapine. CYP2D6 has also been
described to contribute to the metabolism of quetiapine and
aripiprazole. Furthermore, the patient’s ABCB1 genotype may
have contributed to the hyperprolactinemia associated with
amisulpride, to the deep venous thrombosis related to quetiapine,
and, together with CYP2D6, to the sedation due to olanzapine.
While CYP2D6 and CYP3A5 are not always the major metabolic
pathway of drugs associated with AE presented by the patient,
there could be a phenocopy effect related to drugs metabolized
by these pathways.
This complex case illustrates how AE can impact patient
compliance (44), as shown in two hospitalizations (February
2017, May 2017) caused by the patient refusing to continue
the treatment. The patient was prescribed antipsychotics, which
appeared to have repeatedly caused AE. Pharmacogenetic testing
helped to partially understand the origin of his AE; it was possibly
caused by a combination of his pharmacokinetic phenotype
(reduced CYP2D6 and CYP3A5 enzymatic activity and MDR1
expression) and the phenocopy effect related to pharmacokinetic
interactions (Table 2). A treatment plan that was guided by
the patient’s pharmacogenetic profile and knowledge about
the pharmacokinetics of drugs prescribed drastically improved
his medical condition. The patient ultimately reported no AE
and continued to evolve favorably underscoring the utility
of pharmacogenetic testing to guide pharmacotherapy. The
application of this methodology could ensure a significant
reduction in both pharmaceutical (fewer exacerbations hence
less rescue medication, lower dosages, etc.) and hospitalizationrelated (fewer hospitalizations required to manage adverse effects
or achieving better treatment adherence due to the reduction
in the emergence of these adverse effects) economical costs.
Although the evolution of the patient is not certain, the clinical
intervention applied has a lifelong nature, and the results
obtained by the pharmacogenetic analysis could be used by
other medical areas. These conclusions should be considered
taking into account the limitations of this study. Being this
case report based on the application of a recently implemented
approach to our service, we could not make use of all the possible
variables that could be helpful when managing these patients
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